Interim Results to 30 June 2026

AI SummaryClose X

Coiled Therapeutics plc reported a net loss of £3,851,679 for the six months ended 30 June 2026, with cash reserves of £5,099,604 at period end. The company successfully raised £8.5 million in gross proceeds through a placing and subscriptions, which will fund the advancement of its lead asset, AO-252, through key clinical milestones. Positive Phase I data for AO-252 showed an 80% clinical benefit rate in patients receiving twice-daily dosing, with no serious adverse effects reported and the maximum tolerated dose not yet reached. Post-period, a new softgel formulation of AO-252 was developed and dosed, with enrolment completed in initial cohorts. The company's focus remains on generating safety, pharmacokinetic, and efficacy data for the new formulation to support future planning and partner discussions.

Disclaimer*

UK 100

Latest directors dealings